Globeflex Capital L P Takes Position in Anika Therapeutics Inc. $ANIK

Globeflex Capital L P acquired a new position in Anika Therapeutics Inc. (NASDAQ:ANIK) in the 2nd quarter, HoldingsChannel reports. The firm acquired 87,600 shares of the biotechnology company’s stock, valued at approximately $1,282,000.

Several other large investors have also bought and sold shares of the company. CWM LLC increased its position in Anika Therapeutics by 14.5% during the 4th quarter. CWM LLC now owns 8,537 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 1,080 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Anika Therapeutics by 4.3% during the fourth quarter. Corient Private Wealth LLC now owns 32,224 shares of the biotechnology company’s stock valued at $310,000 after acquiring an additional 1,324 shares in the last quarter. Diker Management LLC increased its holdings in shares of Anika Therapeutics by 2.4% during the fourth quarter. Diker Management LLC now owns 58,210 shares of the biotechnology company’s stock valued at $559,000 after acquiring an additional 1,371 shares in the last quarter. Man Group plc raised its position in shares of Anika Therapeutics by 11.4% in the 3rd quarter. Man Group plc now owns 14,778 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 1,510 shares during the last quarter. Finally, Cerity Partners LLC raised its position in shares of Anika Therapeutics by 5.2% in the 4th quarter. Cerity Partners LLC now owns 31,775 shares of the biotechnology company’s stock worth $305,000 after purchasing an additional 1,575 shares during the last quarter. 91.53% of the stock is owned by institutional investors.

Anika Therapeutics Price Performance

Shares of ANIK stock opened at $21.34 on Tuesday. The stock’s fifty day moving average price is $17.19 and its 200 day moving average price is $15.09. Anika Therapeutics Inc. has a 1-year low of $8.37 and a 1-year high of $22.88. The company has a market cap of $285.59 million, a price-to-earnings ratio of -79.03, a price-to-earnings-growth ratio of 15.56 and a beta of 0.20.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.39. The company had revenue of $32.61 million during the quarter, compared to analyst estimates of $29.21 million. Anika Therapeutics had a positive return on equity of 0.20% and a negative net margin of 3.14%. As a group, equities research analysts anticipate that Anika Therapeutics Inc. will post 0.14 earnings per share for the current year.

Analysts Set New Price Targets

ANIK has been the topic of a number of research analyst reports. Wall Street Zen raised Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Wednesday, June 24th. Zacks Research upgraded Anika Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. B. Riley Financial increased their price target on Anika Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Barrington Research set a $21.00 price objective on shares of Anika Therapeutics in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.